% | $
Quotes you view appear here for quick access.

Starbucks Corporation Message Board

  • dansonstevie dansonstevie Sep 20, 2012 2:37 PM Flag

    Think outside the box!! Load up on ECYT!!! Going over $30 soon!!!

    I own a lot of SBUX, but you have to buy ECYT!! or sure they are not allowed right, as then would have offered easy $30 at this moment; but this worth $50+ within 12-18 months

    check pipeline
    ec145 for sure in case of fr++ to be approved
    perhaps, but that might be later fr+
    4 new indications of ec145
    folate + smdc platform

    will rocket higher and soon than MDVW they are at 3 BLN cap, ECYT just $300mln, no debt and enought cash to develop pipeline, with EC145 paid by Merck

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics. Its SMDCs target receptors that are over-expressed on diseased cells, relative to healthy cells. The company's principal SMDC product candidate, EC145, has been evaluated in a randomized Phase II clinical trial for the treatment of women with platinum-resistant ovarian cancer, and it also completed a Phase II single-arm clinical trial for pre-treated non-small cell lung cancer. Its preclinical development products include EC0489 and EC0225, which are in Phase I clinical trial for the treatment of solid cancer tumors; EC17 that has completed Phase I clinical trial for the treatment of solid cancer tumors; EC0531, a tubulysin conjugate to treat solid tumors; and EC0746 and EC0565 foliate receptors for the reduction of inflammation. The company's products under development also comprise EC20, a proprietary companion imaging diagnostic product for the identification of folate receptor in cancer patients; EC1069 for prostate cancer therapy; and EC0652 that is in early clinical trials for use as a companion imaging diagnostic for SMDCs.

      Sentiment: Strong Buy

55.174-0.266(-0.48%)3:55 PMEDT